News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INO Therapeutics Enters Into Agreement With Forest Laboratories, Inc. (FRX) To Co-Promote Infasurf(R) (Calfactant) Intratracheal Suspension



10/19/2005 5:12:36 PM

CLINTON, N.J., Feb. 2 /PRNewswire/ -- INO Therapeutics announced today that it has entered into an agreement with Forest Laboratories, Inc. to co- promote Infasurf using its sales force, which calls on neonatal intensive care units. Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and the treatment ("rescue") of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.

INO Therapeutics LLC is a global pharmaceutical company committed to critical care with a focus in the areas of heart and lung function. INO Therapeutics obtained U.S. Food and Drug Administration approval for INOmax(R) (nitric oxide) for inhalation in 1999. INOmax is the only FDA-approved drug product form of nitric oxide for inhalation.

"We are pleased to add Infasurf to the product offering we bring to neonatologists and their patients in the neonatology intensive care units," said INO Therapeutics President and CEO Dennis Smith. "With INOmax and Infasurf leading our product line, this is just the beginning of pursuing our company vision. We will continue to seek and secure additional products and services for the neonatal and critical care treatment areas."

Administration of exogenous surfactants, including Infasurf, often rapidly improves oxygenation and lung compliance. Following Infasurf administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with Infasurf, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.

For full prescribing information see http://www.infasurf.com/ or call Forest Laboratories' Professional Affairs Department at 1-800-678-1605 Ext. 7301.

INO Therapeutics

CONTACT: Laura Gordon of Edelman Public Relations, +1-202-326-1775, forINO Therapeutics


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES